David Fischer, MD @IgECPD: Dr Jonathan Corren speaking on phenotypes and endotypes of asthma. I remember a talk from years ago when they were conveying asthma was actually ‘asthmas’. We’re finally there…
The hardest asthma phenotype to treat are the non-allergic ones with low FeNO, low eosinophils and are non-atopic. They will often show neutrophils in sputum. They do not benefit from the biological agents we presently have.
Adults patients with asthma have more clear phenotype clusters than pediatric patients with asthma: https://twitter.com/Health_Ontario_/status/1040933321163698177
Eosinophil counts correlate with asthma exacerbation risk. Eosinophils measurements are a classic measuring tool. Sputum and blood both measured. The higher the baseline level of eosinophils the higher the risk of severe exacerbation.
FeNO can predict responsiveness to ICS in asthma. Exhaled nitric oxide predictive of responsiveness to ICS in asthmatics with NO higher than 33 shows good response and NO lower than 20 poor response.
Employment of biomarkers has facilitated the use of new targeted therapies for asthma.
Dr. Mariam Hanna, MD @PedsAllergyDoc
Mary McHenry MD @maryjmchenry
David Fischer, MD @IgECPD
Lori Connors @DrLoriConnors
Dr. A for Allergy MD @Health_Ontario_